Home | Welcome to Contract Pharma   
Last Updated Thursday, June 20 2013
Print RSS Feed

Breaking News

Related Searches:
Porsolt

November 8, 2010
Dr. David Pushett has been appointed director of global business development at Porsolt.   Read More »
BioStorage Technologies

November 8, 2010
Mills to step down as CEO, retain chairman role  Read More »
Cymbalta Approved for Pain Management

November 5, 2010
Eli Lilly and Co. received approval from the FDA for Cymbalta (duloxetine HCl) for the management of chronic musculoskeletal pain.  Read More »
Catalent Adds Xcelodose Micro-dosing System

November 5, 2010
Catalent Pharma Solutions has added the Xcelodose micro-dosing system to its Research Triangle Park (RTP), NC facility.   Read More »
Genentech’s Melanoma Drug Shows Promise

November 5, 2010
Genentech achieved positive results from a Phase II study of RG7204, an investigational molecule designed to selectively inhibit a cancer-causing, mutated form of the BRAF protein found in approximately half of metastatic melanoma tumors.  Read More »
OctoPlus N.V.

November 4, 2010
Jan Hendrik Egberts, M.D. has been appointed chief executive officer of  Read More »
Financial Report: Charles River 3Q10

November 4, 2010
RMS segment sales were $159.3 million in the quarter (-3%) and PCS segment sales were down 13% to $116.8 million.  Read More »
Millennium Advances Prostate Cancer Drug

November 4, 2010
Millennium, The Takeda Oncology Company, has initiated a Phase III trial for TAK-700 in patients with advanced prostate cancer.   Read More »
Biogen Idec Reveals Restructuring Details

November 3, 2010
Operational changes include relocating its U.S. workforce from six current locations into three existing facilities in Weston and Cambridge, MA, and Research Triangle Park, NC.  Read More »
Cambrex Acquires Stake in Indian Formulator

November 3, 2010
Cambrex Corp. has acquired a 51% stake in Zenara Pharma for $20 million.  Read More »
Toxikon Completes Tox Studies for Cellceutix

November 3, 2010
Toxikon Corp. has completed toxicity studies in two species for Cellceutix Corp.’s Kevetrin, a compound in development for the treatment of resistant lung and breast cancers.  Read More »
Financial Report: Pfizer 3Q10

November 2, 2010
Revenues in the quarter were boosted by $5.2 billion, or 44%, due to legacy Wyeth products, and negatively impacted by $458 million, or 4%, due to legacy Pfizer products, including the loss of exclusivity of Lipitor in Canada and Spain, as well as Camptos  Read More »
SGS Acquires M-Scan Group

November 2, 2010
SGS has acquired M-Scan, a group of chemical analysis labs that provides advanced chemical and biochemical testing, GLP/GMP contract analytical services, and consultancy and training based on mass spectrometry and chromatography.  Read More »
Astellas Pharma

November 2, 2010
Donald B. Rice, Ph.D. will retire from Agensys, Inc., an affiliate of Astellas Pharma, Inc.  Read More »
Financial Report: PAREXEL 1Q11

November 2, 2010
Clinical Research Services (CRS) revenue was $231.6 million in the quarter (+14%).  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On
Please visit our sister sites: